FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2977884295> ?p ?o ?g. }

• W2977884295 endingPage "S392" @default.
• W2977884295 startingPage "S392" @default.
• W2977884295 abstract "Introduction: In Romania, hepatitis C virus (HCV)-infection has an overall prevalence of 3.23% and genotype 1b is responsible for >99% of the infections in people who do not inject drugs. Compensated and decompensated cirrhosis is projected to increase by 25-30% by 2030, while liver related mortality was projected to increase by 30% until 2030 in Romania. However, in Romania, the single approved interferon free regimen is ombitasvir/paritaprevir/ritonavir/dasabuvir (3D regimen) and only in F4 fibrosis. The aim of this study was to assess the efficacy and tolerability of 3D regimen in Romanian patients with liver cirrhosis. Methods: 393 consecutive patients with HCV genotype 1b liver cirrhosis and without hepatocellular carcinoma were treated with 3D regimen and ribavirin for 12 weeks in 6 tertiary Gastroenterology/Infectious Diseases Centers from Romania between December 2015 and May 2016. Student T test was used to compare different continuous variables at beginning and at the end of antiviral therapy. Results: There were included 44.5% men and 55.5% women with a mean age of 59±9 years with compensated Child Pugh A liver cirrhosis. 18.8% of the patients had associated diabetes mellitus and 3.3% autoimmune thyroiditis. 58.3% of patients were previously treated with pegylated interferon and 43.2% had esophageal varices. Median baseline viral load was 687000 UI/mL. End of treatment virological response was 100% (only 3 patients had HCV RNA < 15UI/L but still detectable, all the rest had HCV RNA undetectable). Adherence was 100%, none of the patients stopped 3D medications. Ribavirin was stopped after one month due to renal dysfunction in one patient. There was no difference between baseline and EOT for total bilirubin and INR, but creatinine significantly increased (0.80±0.15 vs 0.86±0.21 mg/dL, p < 0.0001). There was a significant decrease of hemoglobin (14.1±1.6 vs 12.3±1.5mg/dL, p< 0.0001) and white blood count (5947.7±3626.4 vs 4816±2773.2/mm3, p < 0.0001) levels at EOT, but a significant increase of platelets (138599.5±71017.4 vs 151881.8±80745/mm3, p < 0.0001). Conclusion: Conclusion: An interferon-free regimen of ombitasvir, paritaprevir, ritonavir, dasabuvir achieved 100% virological response at EOT in patients with HCV GT1b infection with cirrhosis. This regimen was well tolerated and was associated with no treatment discontinuation. Results of SVR12 are pending and will be presented during the meeting." @default.
• W2977884295 created "2019-10-10" @default.
• W2977884295 creator A5000437584 @default.
• W2977884295 creator A5002521179 @default.
• W2977884295 creator A5013811687 @default.
• W2977884295 creator A5021032256 @default.
• W2977884295 creator A5026802895 @default.
• W2977884295 creator A5038707478 @default.
• W2977884295 creator A5039504054 @default.
• W2977884295 creator A5040910618 @default.
• W2977884295 creator A5049988663 @default.
• W2977884295 creator A5050685536 @default.
• W2977884295 creator A5055978007 @default.
• W2977884295 creator A5069052645 @default.
• W2977884295 creator A5069970909 @default.
• W2977884295 creator A5088364476 @default.
• W2977884295 date "2016-10-01" @default.
• W2977884295 modified "2023-10-18" @default.
• W2977884295 title "100% Virological Response and Adherence in HCV Genotype 1 Liver Cirrhosis Treated with 3D Regimen in a Romanian Real-life Cohort" @default.
• W2977884295 doi "https://doi.org/10.14309/00000434-201610001-00898" @default.
• W2977884295 hasPublicationYear "2016" @default.
• W2977884295 type Work @default.
• W2977884295 sameAs 2977884295 @default.
• W2977884295 citedByCount "0" @default.
• W2977884295 crossrefType "journal-article" @default.
• W2977884295 hasAuthorship W2977884295A5000437584 @default.
• W2977884295 hasAuthorship W2977884295A5002521179 @default.
• W2977884295 hasAuthorship W2977884295A5013811687 @default.
• W2977884295 hasAuthorship W2977884295A5021032256 @default.
• W2977884295 hasAuthorship W2977884295A5026802895 @default.
• W2977884295 hasAuthorship W2977884295A5038707478 @default.
• W2977884295 hasAuthorship W2977884295A5039504054 @default.
• W2977884295 hasAuthorship W2977884295A5040910618 @default.
• W2977884295 hasAuthorship W2977884295A5049988663 @default.
• W2977884295 hasAuthorship W2977884295A5050685536 @default.
• W2977884295 hasAuthorship W2977884295A5055978007 @default.
• W2977884295 hasAuthorship W2977884295A5069052645 @default.
• W2977884295 hasAuthorship W2977884295A5069970909 @default.
• W2977884295 hasAuthorship W2977884295A5088364476 @default.
• W2977884295 hasConcept C126322002 @default.
• W2977884295 hasConcept C142462285 @default.
• W2977884295 hasConcept C197934379 @default.
• W2977884295 hasConcept C203014093 @default.
• W2977884295 hasConcept C2522874641 @default.
• W2977884295 hasConcept C2776408679 @default.
• W2977884295 hasConcept C2776455275 @default.
• W2977884295 hasConcept C2776461080 @default.
• W2977884295 hasConcept C2777100407 @default.
• W2977884295 hasConcept C2777214474 @default.
• W2977884295 hasConcept C2778019345 @default.
• W2977884295 hasConcept C2778375690 @default.
• W2977884295 hasConcept C2778390639 @default.
• W2977884295 hasConcept C2778785139 @default.
• W2977884295 hasConcept C2778867932 @default.
• W2977884295 hasConcept C2779298103 @default.
• W2977884295 hasConcept C2780040827 @default.
• W2977884295 hasConcept C2781413609 @default.
• W2977884295 hasConcept C2993143319 @default.
• W2977884295 hasConcept C3013748606 @default.
• W2977884295 hasConcept C71924100 @default.
• W2977884295 hasConcept C90924648 @default.
• W2977884295 hasConceptScore W2977884295C126322002 @default.
• W2977884295 hasConceptScore W2977884295C142462285 @default.
• W2977884295 hasConceptScore W2977884295C197934379 @default.
• W2977884295 hasConceptScore W2977884295C203014093 @default.
• W2977884295 hasConceptScore W2977884295C2522874641 @default.
• W2977884295 hasConceptScore W2977884295C2776408679 @default.
• W2977884295 hasConceptScore W2977884295C2776455275 @default.
• W2977884295 hasConceptScore W2977884295C2776461080 @default.
• W2977884295 hasConceptScore W2977884295C2777100407 @default.
• W2977884295 hasConceptScore W2977884295C2777214474 @default.
• W2977884295 hasConceptScore W2977884295C2778019345 @default.
• W2977884295 hasConceptScore W2977884295C2778375690 @default.
• W2977884295 hasConceptScore W2977884295C2778390639 @default.
• W2977884295 hasConceptScore W2977884295C2778785139 @default.
• W2977884295 hasConceptScore W2977884295C2778867932 @default.
• W2977884295 hasConceptScore W2977884295C2779298103 @default.
• W2977884295 hasConceptScore W2977884295C2780040827 @default.
• W2977884295 hasConceptScore W2977884295C2781413609 @default.
• W2977884295 hasConceptScore W2977884295C2993143319 @default.
• W2977884295 hasConceptScore W2977884295C3013748606 @default.
• W2977884295 hasConceptScore W2977884295C71924100 @default.
• W2977884295 hasConceptScore W2977884295C90924648 @default.
• W2977884295 hasLocation W29778842951 @default.
• W2977884295 hasOpenAccess W2977884295 @default.
• W2977884295 hasPrimaryLocation W29778842951 @default.
• W2977884295 hasRelatedWork W2323574296 @default.
• W2977884295 hasRelatedWork W2339494956 @default.
• W2977884295 hasRelatedWork W2410965428 @default.
• W2977884295 hasRelatedWork W2552228682 @default.
• W2977884295 hasRelatedWork W2565807151 @default.
• W2977884295 hasRelatedWork W2587635005 @default.
• W2977884295 hasRelatedWork W2599775621 @default.
• W2977884295 hasRelatedWork W2606761732 @default.
• W2977884295 hasRelatedWork W2912361910 @default.
• W2977884295 hasRelatedWork W2984583494 @default.
• W2977884295 hasVolume "111" @default.
• W2977884295 isParatext "false" @default.

• next